Axl as a therapeutic target in metastatic ovarian cancer
- Katherine Cynthia Fuh.
- Aug. 2013.
- Physical description
- online resource (xi, 109 pages) : illustrations (some color)
- Fuh, Katherine Cynthia.
- Cochran, Jennifer R. thesis advisor.
- Giaccia, Amato J. thesis advisor (primary).
- Hu, Mickey. thesis advisor.
- Sweet-Cordero, Eric thesis advisor.
- Stanford University. Program in Cancer Biology.
- Stanford University. Committee on Graduate Studies. degree grantor.
- Includes bibliographical references.
- ["Axl, Sky, and Mer receptor tyrosine kinases (RTKs) are increasingly implicated in a host of cellular responses including cell survival, proliferation, migration, phagocytosis, chemoresistance, and epithelial-mesenchymal transition (EMT). Furthermore, the Gas6/AXL system is implicated in several types of human cancer as well as inflammatory, autoimmune, vascular and kidney diseases. Since the discovery of Gas6/AXL in 1988 in chronic myelogenous leukemia, many more cancers have been found to express AXL. In chapter 1, I will describe my contribution to the field that includes identifying the role of AXL in metastatic ovarian cancer and validating the therapeutic target in ovarian cancer. In the second chapter, I have investigated the role of AXL in chemoresistance in ovarian cancer. Within the past decade, AXL crosstalk has emerged as a dominant pathway for ligand-independent activation. With the recent identification of AXL as an important factor in mediating tyrosine kinase inhibitor resistance, understanding this cross-talk is important. There has been a recent report of c-MET and AXL cross-talk in breast cancer. c-MET has become a potential target for cancer therapy with numerous clinical trials using c-MET inhibitors as monotherapy or in combination with other targeted agents or chemotherapy. I have further explored this cross-talk in ovarian cancer. In my final chapter, I have identified AXL expression in ovarian cancer tumors formed in a conditional genetically modified invasive ovarian cancer mouse model. In the future, AXL therapy should be further investigated in patients with metastatic ovarian cancer."]
- Ovarian Neoplasms > enzymology
- Ovarian Neoplasms > therapy
- Proto-Oncogene Proteins > antagonists & inhibitors
- Receptor Protein-Tyrosine Kinases > antagonists & inhibitors
- Neoplasm Metastasis
- Signal Transduction
- Publication date
- Submitted to the Cancer Biology Program and the Committee on Graduate Studies of Stanford University.
- Thesis (Ph.D.)--Stanford University, 2013.